ND-13, a DJ-1 derived peptide, as a novel pharmacological approach in the prevention of NLRP3 inflammasome activity in Diabetic Nephropathy
Authors: Caballero-Herrero María José , Arias-Sánchez Celia , Quevedo Ignacio , S. Latham Patricia , Miguel Carmen De , Zhong Yihan , Xu Gaoxi , Guillen Estela , Núñez-Sancho Adrián , Angosto Diego , Molina-López Cristina , Hurtado-Navarro Laura , Schachter Julieta , Pardo Marín Luis , Cerón José Joaquín , Hernandez-Martinez Antonio M , Rosique López Florentina , Andúgar Rocamora Leonor , B Cabezuelo Juan , Pelegrin Pablo , Cuevas Santiago 
Published: January 2025

AbstractDiabetic nephropathy is the most important cause of renal failure worldwide and is characterized by sustained inflammation regulated in part by NLRP3 Inflammasome. Attenuation of inflammation is a major priority to prevent renal damage. Our previous publications show that DJ-1 has antioxidant and anti-inflammatory properties in the kidney. ND-13 is a short peptide consisting of 13 amino acids of the DJ-1-protein, which could increase DJ-1 pathway activation. The aim of these studies was to determine the role of NLRP3 in the pathogenesis of diabetic nephropathy and to study the possible renal protective effects of the DJ-1 pathway in diabetic mice and on inflammasome regulation.Bone marrow derived macrophages were treated with ND-13 and cultivated in high and low glucose. Diabetes was induced in C57Bl/6 mice via injection of streptozotocin and treated with ND-13 and MCC950, an inhibitor of the NLRP3 inflammasome. Peripheral mononuclear cells were isolated from human with diabetes, diabetic nephropathy and healthy donors and were plated, pretreated with ND-13 and stimulated with LPS+ATP.IL-1β concentration in the medium of bone marrow derived macrophages increased by NLRP3 inflammasome stimulation by LPS+ATP, and decreased in macrophages pre-treated with ND-13, however, in the presence of LPS+Nigericin no effect was found. Peritoneal macrophages from diabetic mice were obtained and plated. Streptozotocin-induced diabetic C57BL/6 mice have increased the peritoneal cells IL-1β production compared with control mice, suggesting that inflammasome may be activated in macrophages during diabetes and that ND-13 treatment normalized its activity. ND-13 and MCC950 decreased histologic evidence of tubular injury in STZ-induced diabetes in mice, additionally, significantly increased the mRNA expression ofCol-I, Col-II, Tgf-β, Il-6, Tnf-αandP2x7in the renal cortex, which was partially prevented by ND-13 and MCC950 pre-treatment.P2x7mRNA expression was also increased in peritoneal macrophages obtained from diabetic mice, and its expression was attenuated by ND-13 pre-treatment. Peripheral mononuclear cells isolated from patient’s blood were plated and stimulated with LPS+ATP. Patients with diabetic nephropathy presented a significant increase of IL-1β release compared to diabetic individuals and ND-13 could has a role in the prevention of inflammasome activation in healthy patients.Our results demonstrate that activation of the DJ-1 pathway is a promising approach to prevent renal inflammation and fibrosis during diabetes, by ameliorating inflammasome activation in peripheral immune cells. Thus, ND-13 could be a promising new therapeutic approach to attenuating inflammation and renal damage in diabetic nephropathy.